Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 10, 2015, Pages 1319-1328

  Zuraw, B L ^a   Cicardi, M ^b   Longhurst, H J ^c   Bernstein, J A ^d   Li, H H ^e   Magerl, M ^f   Martinez Saguer, I ^g   Rehman, S M M ^h   Staubach, P ⁱ   Feuersenger, H ^j   Parasrampuria, R ^k   Sidhu, J ^l   Edelman, J ^k   Craig, T ^m  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e Institute for Asthma and Allergy   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HZRM Haemophilia Centre Rhine Main   (Germany)

^h Allergy and Asthma Research Center   (United States)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j CSL BEHRING GMBH   (Germany)

^k CSL BEHRING   (United States)

^l CSL LIMITED   (Australia)

^m PENNSYLVANIA STATE UNIVERSITY   (United States)

more..

Author keywords

Berinert; C1 esterase inhibitor; hereditary angioedema; long term prophylaxis; subcutaneous treatment

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4;

ADULT; AGED; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FAINTNESS; FEMALE; HUMAN; HYPOVOLEMIC SHOCK; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; OPEN STUDY; PEAK-TROUGH FLUCTUATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; STEADY STATE; SUBSTITUTION THERAPY; VOLUME OF DISTRIBUTION; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942363387     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12658     Document Type: Article

References (28)

1. Frank MM, Gelfand JA, Atkinson JP,. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580-593.
2. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A,. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284: 2-9.
3. Zuraw BL,. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
4. Bork K, Hardt J, Witzke G,. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-697.
5. Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, et al., US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1: 458-467.
6. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al., 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24-36.
7. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al., Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
8. Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, et al., WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
9. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, et al., International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012; 109: 395-402.
10. Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, et al., A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol 2013; 131: 1491-1493.
11. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al., Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-616.
12. Zuraw BL, Busse PJK, White M, Jacobs J, Lumry W, Baker J, et al., Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
13. Waytes AT, Rosen FS, Frank MM,. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-1634.
14. Wagenaar-Bos IG, Drouet C, Aygören-Pursun E, Bork K, Bucher C, Bygum A, et al., Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008; 338: 14-20.
15. Kelemen Z, Moldovan D, Mihaly E, Visy B, Szeplaki G, Csuka D, et al., Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol 2010; 134: 354-358.
16. Späth PJ, Wüthrich B, Bütler R,. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema-evidence of a functionally critical level of C1-inhibitor concentration. Complement 1984; 1: 147-159.
17. Martinez-Saguer I, Cicardi M, Suffritti C, Rusicke E, Aygören-Pürsün E, Stoll H, et al., Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion 2014; 54: 1552-1561.
18. Gandhi PK, Gentry WM, Bottorff MB,. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012; 32: 902-909.
19. Kalaria S, Craig T,. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc 2013; 34: 519-522.
20. Frank MM,. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653-668.
21. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M,. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-196.
22. Frank MM,. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am 2013; 33: 495-503.
23. Xu YY, Buyantseva LV, Agarwal NS, Olivieri K, Zhi YX, Craig TJ,. Update on treatment of hereditary angioedema. Clin Exp Allergy 2013; 43: 395-405.
24. Bork K, Bygum A, Hardt J,. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-161.
25. Füst G, Farkas H, Csuka D, Varga L, Bork K,. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011; 41: 256-262.
26. Richter WF, Bhansali SG, Morris ME,. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 2012; 14: 559-570.
27. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA,. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 2010; 12: 461-470.
28. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS,. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71: 1041-1046.